Niagen Bioscience Inc (FRA:OCD1)

Q4 2025 Niagen Bioscience Inc Earnings Call Transcript

Mar 4, 2026 / 09:30 PM GMT

Release Date Price: €4 (+0.50%)

Transcript 8-K10-K

Key Points

Positve

Niagen Bioscience Inc (NAGE) reported a strong financial performance with a 16% year-over-year revenue growth in Q4 2025, reaching $33.8 million.
The company achieved a 30% year-over-year growth in net revenue for the full year 2025, totaling $129.4 million.
Niagen Bioscience Inc (NAGE) ended the year with $64.8 million in cash and no debt, indicating strong financial health.
The company secured a patent for NR and derivatives in intravenous and injectable formulations, expanding its product offerings.
Niagen Bioscience Inc (NAGE) continues to lead in NAD science, with 29 studies published since the last earnings call, including 8 clinical studies.

Negative

Increased competition in the NAD space poses a challenge for Niagen Bioscience Inc (NAGE).
The FDA's reversal on NMN's status as a dietary supplement has created industry confusion and led to litigation.
The No Park Parkinson's study did not achieve its primary endpoint, indicating challenges in proving NR's efficacy for Parkinson's disease.
General and administrative expenses increased by $8.7 million year-over-year, driven by higher employee-related expenses and stock-based compensation.
The company's guidance for 2026 projects a lower growth rate of 10-15% compared to the 30% growth achieved in 2025.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NAGE.OQ - Niagen Bioscience Inc
Q4 2025 Niagen Bioscience Inc Earnings Call
Mar 04, 2026 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for standing by and welcome to Niogen Bioscience Inc. 4th quarter of 2025 earnings conference call. My name is Tiffany and I'll be the conference operator today.

At this time, all participants are in a listen-only mode, and as a reminder, this conference call is being recorded.

This afternoon Nrogen Bioscience issued a news release announcing the company's financial results for the 4th quarter of 2025.

If you have not reviewed this information, both are available within the investor relations section of Niogen Bioscience website at www.nanogenbioscience.com.

I would now like to turn the conference call over to Kendall Kanish, senior director of Publicity and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.